Judge Awards Summary Judgment to Roche on Off-Label Injury Claim



DOCUMENTS
  • Order


DALLAS - FDA approval of a drug, even when prescribed for off-label use, precludes state law claims for failure to warn where there is no evidence rebutting the presumption that the drug's warnings were adequate, a judge has ruled. Holland v. Hoffman-La Roche Inc., No. 06-1298 (N.D. Texas).

Awarding summary judgment Nov. 15 to Hoffman-La Roche Inc., Judge Jeff Kaplan of the U.S. District Court for the Northern District of Texas dismissed with prejudice a case brought by a plaintiff who claimed he developed a severe eye infection and sepsis as a result of taking the company's CellCept drug.

Rickey …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Video Game Addiction Product Liability Litigation

March 29, 2024

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS